Published in Medical Letter on the CDC and FDA, May 25th, 2008
Total revenues for the first quarter of 2008 grew 62 percent to $42.7 million from $26.4 million in 2007, primarily from growth in sales of BioThrax(R) (Anthrax Vaccine Adsorbed). Net income for the first quarter of 2008 was $7.0 million, or $0.24 per share, in comparison to a net loss of $2.7 million, or $0.10 per share, for the comparable period in 2007.
R. Don Elsey, Emergent BioSolutions' chief financial officer, said, "Our first quarter 2008 financial performance reflects the continued strength of our business approach of generating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.